vociprotafib + pembrolizumab

**vociprotafib + pembrolizumab** is an investigational combination therapy being studied in advanced malignancies, especially advanced solid tumors. - **Vociprotafib** (RMC-4630, SAR442720) is a small molecule inhibitor of SHP2, a tyrosine phosphatase that facilitates RAS/MAPK signaling downstream of KRAS and related oncogenes. By inhibiting SHP2, vociprotafib impairs oncogenic RAS-driven cell signaling, especially in tumors with KRAS, BRAF, or NF1 mutations. - **Pembrolizumab** is a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) on T-cells, thereby blocking the PD-1/PD-L1 axis and allowing T-cell mediated immune responses against tumor cells. The rationale for the combination is that SHP2 inhibition may enhance tumor immunogenicity, sensitize tumors to immunotherapy, and overcome resistance to checkpoint blockade. This combination is under investigation in Phase 1/2 trials for safety and preliminary efficacy in advanced solid tumors, particularly those with KRAS, BRAF, or NF1 mutations[3][1].

Other names

vociprotafibpembrolizumab